Health Condition 1: N202- Calculus of kidney with calculus of ureter
Conditions
Interventions
Intervention1: DOUBLE BLINDED CROSS OVER INTERVENTIONAL CLINICAL TRIAL
â?¢ This crossover clinical trial is a repeated measures design study in which each patient is randomly assigned to a sequence o
Sponsors
State Board of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients who have been diagnosed as having calcium oxalate urinary stones 2.Between 15-65 years of age 3.With body mass index (BMI) between 18 and 30 kg/m2 4.willing to adhere to a low calcium diet for the duration of study (about 15 days)
Exclusion criteria
Exclusion criteria: 1.Patients with Obstructive Uropathy, Chronic Urosepsis / Positive Urine Culture, Renal failure, (S. Creatinine > 2.0 mg %) Renal Tubular Acidosis, Primary Hyperoxaluria, Medullary Sponge Kidney. 2.Patients with anatomical abnormalities of the Urinary Tracts 3.Have a serious alternate disease that might affect completion of the study or jeopardize the study, like a known medical history of calcium or vitamin D malabsorption, leading to hypercalcemia and hypercalciuria, any current or recent diagnosis thought to affect bone or mineral metabolism or parameters related to calcium bioavailability such as hypo- or hyperparathyroidism, hypothyroidism, dyslipidemia, liver disease, or diabetes mellitus. 4.Patients taking any medications like corticosteroids or proton pump inhibitors had any clinically significant illness within 30 days of the start of the study, 5.Pregnancy 6.Active cancer 7.Recurrent urinary infections 8.Gross hematuria 9.Receiving treatment with thiazides (or alternatively can be enrolled if the patient is willing to stop treatment for 2 weeks prior to study) 10.Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that Calcium Citrate Malleate will be a better calcium supplement than Calcium Carbonate in calcium oxalate stone formers.Timepoint: 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The urine samples of the patients after drug administration should show optimum optical density values and risk for crystallisation.Timepoint: One, three and six months after starting therapy. | — |
Countries
India
Contacts
Public ContactDrGSathish Kumar
GOVT. MEDICAL COLLEGE, THIRUVANANTHAPURAM
Outcome results
None listed